Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

GeneTether Therapeutics Inc. (C:GTTX)

Business Focus: Biotechnology & Medical Research (NEC)

Nov 28, 2023 05:35 pm ET
GeneTether Therapeutics Inc. Announces Third Quarter 2023 Financial Results
Vancouver, British Columbia - TheNewswire - November 28, 2023 - GeneTether Therapeutics Inc. (together with its wholly-owned subsidiary GeneTether, Inc., “GeneTether” or the “Company”) (CSE:GTTX) announced today the filing of its interim condensed consolidated financial statements for the period ending September 30, 2023. All dollar amounts are presented in the United States dollar, unless otherwise noted. Complete financial statements along with the related Management’s Discussion and Analysis can be found under the Company’s profile on the SEDAR+ website at www.sedarplus.ca. SEDAR+ is the e
Oct 20, 2023 05:30 am ET
GeneTether Therapeutics Board Provides Shareholder Update
Vancouver, British Columbia – TheNewswire - October 20, 2023 – GeneTether Therapeutics Inc., (together with its wholly-owned subsidiary GeneTether, Inc., “GeneTether” or the “Company”) (CSE:GTTX), today provided the following update to shareholders from the Company’s Board of Directors:
May 01, 2023 03:00 am ET
GeneTether Therapeutics Engages Gad Berdugo, Managing Partner of Explorium Capital LLC, as Advisor to Explore Strategic Alternatives for GeneTether Technology Platform
Vancouver, British Columbia – TheNewswire - May 1st, 2023 - GeneTether Therapeutics Inc. (“GeneTether” or the “Company”) (CSE:GTTX), is pleased to announce the engagement of Mr. Gad Berdugo, Managing Partner of Explorium Capital LLC, as an advisor to explore strategic alternatives for its GeneTether™ platform technology. Mr. Berdugo, who served as the former Chief Business Officer of gene editing pioneer, Editas, brings more than 25 years of biotech corporate development, business development, strategy, and financial experience. Among his prior roles, Mr. Berdugo held several executive-level
Nov 25, 2022 02:30 pm ET
GeneTether Therapeutics Inc. Announces Third Quarter 2022 Financial Results and Reports on Corporate Highlights
Vancouver, British Columbia –  TheNewswire - November 25, 2022 – GeneTether Therapeutics Inc. (“GeneTether” or the “Company”) (CSE:GTTX), announced today the filing of its interim condensed consolidated financial statements for the period ending September 30, 2022 and reported on corporate highlights for the third quarter of fiscal 2022. GeneTether is an early-stage genetic medicine company focused on developing its disruptive proprietary GeneTether™ platform technology, which is designed to significantly increase the efficiency of DNA insertion into the genome. All dollar amounts are present
Oct 25, 2022 11:00 am ET
GeneTether Therapeutics Inc. Update - From the Desk of the CEO
Vancouver, British Columbia – TheNewswire - October 25, 2022 – GeneTether Therapeutics Inc. (“GeneTether” or the “Company”) (CSE:GTTX) is pleased to provide an update from the CEO.
Aug 26, 2022 02:40 pm ET
The Power Play by The Market Herald Releases New Interviews with Datametrex, Cloud DX, Alkaline, and GeneTether Therapeutics
VANCOUVER, BC / ACCESSWIRE / August 26, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Datametrex, Cloud DX, Alkaline, and GeneTether Therapeutics on their latest news.
Aug 25, 2022 10:20 am ET
GeneTether Therapeutics Inc. Announces Second Quarter 2022 Financial Results and Reports on Corporate Highlights
Vancouver, British Columbia – TheNewswire - August 24, 2022 – GeneTether Therapeutics Inc. (“GeneTether” or the “Company”) (CSE:GTTX), (CNSX:GTTX.CN), announced today the filing of its interim condensed consolidated financial statements for the period ending June 30, 2022 and reported on corporate highlights for the second quarter of fiscal 2022. GeneTether is an early-stage genetic medicine company focused on developing its disruptive proprietary GeneTether™ platform technology, which is designed to significantly increase the efficiency of DNA insertion into the genome. All dollar amounts ar
May 30, 2022 04:20 pm ET
The Power Play by The Market Herald Releases New Interview with GeneTether Therapeutics
VANCOUVER, BC / ACCESSWIRE / May 30, 2022 / The Power Play by The Market Herald has announced the release of a new interview with GeneTether Therapeutics on their latest news.
May 25, 2022 09:00 am ET
GeneTether Therapeutics Announces Issuance of New US Composition of Matter Patent for its Innovative Platform Technology Focused on Gene Editing Efficiency
U.S. Pat. No. 11,339,385 was issued on May 24, 2022, by the U.S. Patent and Trademark Office for the composition of matter of the GeneTether™ platform technologyThe patent has an expiration date of July 14, 2040SAN LORENZO, Calif. and VANCOUVER, BC, May 25, 2022 /CNW/ - GeneTether Therapeutics Inc., ("GeneTether" or the "Company") (CSE: GTTX) announced today that the United States Patent and Trademark Office has granted patent #11,339,385 entitled "Modified Nucleic Acid Editing Systems for Tethering Donor DNA" related to its GeneTether platform technology. The claims cover a composition of m
Mar 30, 2022 02:10 pm ET
The Power Play by The Market Herald Releases Interviews With Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp.
VANCOUVER, BC / ACCESSWIRE / March 30, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp. on their latest news.
Mar 29, 2022 09:06 am ET
GeneTether Therapeutics Completes Initial Public Offering and Announces Listing on the Canadian Securities Exchange
/NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Mar 28, 2022 02:24 pm ET
CSE Bulletin: New Listing - GeneTether Therapeutics Inc. (GTTX)
Toronto, Ontario--(Newsfile Corp. - Le 28 mars/March 2022) - The common shares of GeneTether Therapeutics Inc., have been approved for listing on the CSE.